![]() protein-drug conjugates, RNA, radiopharmaceuticals, radioimmunotherapy) Identifying and targeting novel DNA repair and DNA damage response pathways modulating tumorigenesis and therapeutic response.Caveolae-mediated endocytosis and nutrient scavenging. ![]() We collaborate with many other labs at City of Hope, across the U.S., and internationally in five main overlapping research areas with the goal to drive development of new clinical trials: We identify and validate our biomarkers in clinically-relevant disease model systems for the diagnosis, treatment and prognosis of cancer patients. We use various mouse models (transgenic, genetically-engineered, patient-derived xenograft, and orthotopic models) as well as patient tissues (tumor and normal) in combination with basic molecular and cellular techniques to address the fundamental cancer biological questions about how cancers initiate, develop, and progress to aggressive, therapeutically-resistant, and metastatic disease. Such knowledge allows us to design and implement novel therapy strategies for poor-prognosis cancers, including gastrointestinal (pancreatic, esophago- gastric, colorectal, and hepatobiliary), thoracic (non-small cell lung cancer), thyroid, and head and neck malignancies. The overarching goal of our research is to understand the mechanisms of the inherent and acquired resistance of cancer cells to current available treatment modalities, particularly radiotherapy and chemotherapy at the genetic, transcriptomic, and proteomic levels.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |